The global trend is for a continued decrease in the number of CABG procedures and an increase in the number of percutaneous coronary intervention procedures. Typically about 90% of all percutaneous coronary intervention procedures use a coronary stent in the developed economies with approximately 75% of all procedures that use stents do so with drug-eluting stents (DES) and this percentage continues to increase.
For the vast majority of cases of coronary artery disease, the treatment options are typically limited to angioplasty alone or with stents or coronary artery bypass grafting. Aside from the advent of new device and equipment technologies to perform coronary artery bypass via catheter or otherwise in minimally invasive formats (such as minimally invasive direct coronary artery bypass, or MIDCAB), the market for the treatment of coronary artery bypass is largely represented by interventional cardiology, comprised of the following products:
- Global sales of coronary guide wires, balloon dilatation catheters, guiding catheters and accessories
- Vascular closure devices
See the White Paper on Coronary Stents (see the “DOWNLOAD” button) and the associated report, “The Future of Coronary Artery Disease Medical Devices to 2021“, published by Smithers Apex.